Europe Intrauterine devices (IUD’S) Market was worth USD 353.52 million in 2018 and estimated to reach USD 451.19 million by the end of 2023 with a growing potential of 5.00 % during the forecast period 2018-2023.
Intrauterine devices (IUDs) are contraceptive medical implants used to avoid pregnancies for a long time period. IUD’S are also known as long-acting reversible contraceptive devices. An IUD is a T-shaped device which is made of flexible plastic along with a copper wire wrapped around its stem and is a reliable and safe method of sterilization for women. It is injected into the uterus, and their primary aim is to inhibit the fertilization of the egg by causing changes, such as toxicity or thickening of the cervical mucus, thus inhibiting fertilization by a sperm. Mirena, Skyla and Paragard are some of the prominent brands available in the market. Growing incidence of unwanted pregnancies are accomplishing popularity, as intrauterine devices helps to limit the health care expenditure on abortions.
Europe intrauterine Device market is mainly driven by the factors such as Advancement in technical innovations, increasing prevalence of STD’S (Sexually transmitted diseases), instant health benefits other than birth control, increasing government initiatives to prevent unwanted abortions and pregnancies. The factors that hinder the growth of the market are Infertility issues, Economic constraints, and Limited access to contraception.
On the Basis of Geography, the Europe Intrauterine Devices Market is bifurcated into the France, Italy, Germany, Spain and UK. The largest share in the market is held by Hormonal IUD’S. Since, they have less risks compared to non-hormonal IUD’S.
This research report segmented and sub-segmented the Europe Intrauterine Devices Market into the following categories:
By Product: hormonal and copper IUDs.
By End User: Hospitals, gynecology clinics, community healthcare, and Others.
By Country: France, Germany, Italy, Spain, and the UK
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Hormonal Intrauterine Devices
5.1.2 Copper Intrauterine Devices
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Agile Therapeutics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Actavis PLC
8.3 ANI Pharmaceuticals
8.4 Bayer
8.5 Teva Pharmaceutical
8.6 Besins HealthCare
8.7 Brecuro Medical
8.8 Effik International
8.9 Eurogine
8.10 HLL Lifecare
8.11 HRA Pharma
8.12 Lupin Pharmaceuticals
8.13 Okamato Industries
8.14 Pfizer
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market outlook and Investment oppurtunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
